HTG Molecular Diagnostics (NASDAQ: HTGM) is one of 24 publicly-traded companies in the “Analytical instruments” industry, but how does it contrast to its peers? We will compare HTG Molecular Diagnostics to similar businesses based on the strength of its institutional ownership, valuation, analyst recommendations, risk, earnings, dividends and profitability.
Insider & Institutional Ownership
7.3% of HTG Molecular Diagnostics shares are held by institutional investors. Comparatively, 57.9% of shares of all “Analytical instruments” companies are held by institutional investors. 7.6% of HTG Molecular Diagnostics shares are held by company insiders. Comparatively, 13.2% of shares of all “Analytical instruments” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This table compares HTG Molecular Diagnostics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|HTG Molecular Diagnostics||-128.46%||N/A||-109.14%|
|HTG Molecular Diagnostics Competitors||-211.21%||-3,010.19%||-16.76%|
Volatility & Risk
HTG Molecular Diagnostics has a beta of 1.63, meaning that its stock price is 63% more volatile than the S&P 500. Comparatively, HTG Molecular Diagnostics’ peers have a beta of 1.11, meaning that their average stock price is 11% more volatile than the S&P 500.
Earnings and Valuation
This table compares HTG Molecular Diagnostics and its peers revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|HTG Molecular Diagnostics||$14.76 million||-$18.96 million||-1.86|
|HTG Molecular Diagnostics Competitors||$1.09 billion||$107.39 million||21.47|
HTG Molecular Diagnostics’ peers have higher revenue and earnings than HTG Molecular Diagnostics. HTG Molecular Diagnostics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This is a breakdown of current recommendations for HTG Molecular Diagnostics and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|HTG Molecular Diagnostics||0||0||3||0||3.00|
|HTG Molecular Diagnostics Competitors||97||714||1086||44||2.55|
HTG Molecular Diagnostics currently has a consensus target price of $6.67, suggesting a potential upside of 100.20%. As a group, “Analytical instruments” companies have a potential upside of 15.25%. Given HTG Molecular Diagnostics’ stronger consensus rating and higher probable upside, equities analysts clearly believe HTG Molecular Diagnostics is more favorable than its peers.
HTG Molecular Diagnostics peers beat HTG Molecular Diagnostics on 7 of the 13 factors compared.
About HTG Molecular Diagnostics
HTG Molecular Diagnostics, Inc. is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development. The Company’s HTG Edge and HTG EdgeSeq platforms automate the molecular profiling of genes and gene activity using its nuclease protection chemistry on a range of biological samples. The Company’s HTG EdgeSeq chemistry, together with its HTG Edge or HTG EdgeSeq instrumentation and software, automates and adapts its nuclease protection chemistry to enable analysis using next generation sequencing (NGS) instrumentation. The HTG EdgeSeq system utilizes substantially the same sample preparation reagents as its original chemistry, but allows for read out on an NGS instrument.
Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.